The present invention relates to compounds of the formula I: ##STR00001## wherein R.sup.1 to R.sup.8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.